{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:42:46Z","timestamp":1767890566254,"version":"3.49.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01787-9","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T01:58:04Z","timestamp":1752544684000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Second allogeneic stem cell transplantation using different donors as the salvage treatment for acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1007","volume":"25","author":[{"given":"Zhanxiang","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erhui","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuhao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongqiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanzhi","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"1787_CR1","unstructured":"D\u00f6hner HA-O et al. AML 2022 ELN. In: Blood, 2022 (1528\u20130020 (Electronic))."},{"key":"1787_CR2","unstructured":"Pollyea DA et al. Acute Myeloid Leukemia, version 3.2023, NCCN clinical practice guidelines in oncology. (1540\u20131413 (Electronic))."},{"issue":"1","key":"1787_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.clml.2022.08.014","volume":"23","author":"A Kopi\u0144ska","year":"2023","unstructured":"Kopi\u0144ska A, et al. Allogeneic hematopoietic stem cell transplantation for relapsed\/refractory acute myeloid leukemia: a single-centre experience. Clin Lymphoma Myeloma Leuk. 2023;23(1):28\u201339.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1787_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15077","author":"AA-OX Rashidi","year":"2018","unstructured":"Rashidi AA-OX, Weisdorf DJ, Bejanyan N. Treatment of relapsed\/refractory acute myeloid leukaemia in adults. Br J Haematol. 2018. https:\/\/doi.org\/10.1111\/bjh.15077.","journal-title":"Br J Haematol"},{"key":"1787_CR5","doi-asserted-by":"crossref","unstructured":"Thol FHA-O, D\u00f6hner AA-O, Ganser How I treat refractory and relapsed acute myeloid leukemia. In: Blood, 2024(1528\u20130020 (Electronic)).","DOI":"10.1182\/blood.2023022481"},{"key":"1787_CR6","doi-asserted-by":"crossref","unstructured":"Thol F, Ganser A Treatment of Relapsed Acute Myeloid Leukemia. 2020(1534\u20136277 (Electronic)).","DOI":"10.1007\/s11864-020-00765-5"},{"issue":"3","key":"1787_CR7","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","volume":"21","author":"N Bejanyan","year":"2015","unstructured":"Bejanyan N, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and Marrow transplant research study. Biol Blood Marrow Transplant. 2015;21(3):454\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1787_CR8","unstructured":"Devillier R et al. Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia. In: Leukemia & Lymphoma, 2013(1029\u20132403 (Electronic))."},{"key":"1787_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03416-7","author":"F Kreidieh","year":"2022","unstructured":"Kreidieh F, et al. Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment. Int J Hematol. 2022. https:\/\/doi.org\/10.1007\/s12185-022-03416-7.","journal-title":"Int J Hematol"},{"key":"1787_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-01985-7","author":"GA-O Filippini Vel\u00e1zquez","year":"2023","unstructured":"Filippini Vel\u00e1zquez GA-O, et al. Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia-a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European society for blood and marrow transplantation (EBMT). Bone Marrow Transplant. 2023. https:\/\/doi.org\/10.1038\/s41409-023-01985-7.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"1787_CR11","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1038\/s41375-024-02318-3","volume":"38","author":"O Penack","year":"2024","unstructured":"Penack O, et al. How risky is a second allogeneic stem cell transplantation? Leukemia. 2024;38(8):1799\u2013807.","journal-title":"Leukemia"},{"key":"1787_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.186","author":"T Ruutu","year":"2015","unstructured":"Ruutu T, et al. Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. Bone Marrow Transplant. 2015. https:\/\/doi.org\/10.1038\/bmt.2015.186.","journal-title":"Bone Marrow Transplant"},{"key":"1787_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.221","author":"R Vrhovac","year":"2016","unstructured":"Vrhovac R, et al. Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes. Bone Marrow Transplant. 2016. https:\/\/doi.org\/10.1038\/bmt.2015.221.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"1787_CR14","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.bbmt.2015.11.012","volume":"22","author":"G Orti","year":"2016","unstructured":"Orti G, et al. Outcome of second allogeneic hematopoietic cell transplantation after relapse of myeloid malignancies following allogeneic hematopoietic cell transplantation: a retrospective cohort on behalf of the Grupo Espa\u00f1ol de Trasplante Hematopoyetico. Biol Blood Marrow Transplant. 2016;22(3):584\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1787_CR15","unstructured":"Weisdorf D, The role of second transplants for leukemia. (1532\u20131924 (Electronic))."},{"key":"1787_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15048","author":"YA-O Wei","year":"2021","unstructured":"Wei YA-O, et al. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome. Cancer Sci. 2021. https:\/\/doi.org\/10.1111\/cas.15048.","journal-title":"Cancer Sci"},{"key":"1787_CR17","doi-asserted-by":"crossref","unstructured":"Senapati J, Kadia TM, Ravandi F, Maintenance therapy in acute myeloid leukemia: advances and controversies. 2023(1592\u20138721 (Electronic)).","DOI":"10.3324\/haematol.2022.281810"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01787-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01787-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01787-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:47:00Z","timestamp":1764917220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01787-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1787"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01787-9","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have stated that they have no conflicts of interest and other Ethics Statement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"249"}}